Soluble urokinase plasminogen activator receptor (suPAR) is a potential biomarker of stage III-IV, grade C periodontitis through the impact of post-radiotherapy on head and neck cancer patients
The study was registered retrospectively; clinicaltrials.gov identifier: NCT06529588. Date of registration: July 31, 2024 https://clinicaltrials.gov/study/NCT06529588 .
Authors
- Hamid Hammad Enezei (ORCID: https://orcid.org/0000-0002-6182-6020)
- Nisreen Salah Majeed
- Maysam Abdulrahman Ghazi
- Ahmed A. Al-Kubaisi
- Ekram R. Aldelaimi
Institutions
- University of Anbar (IQ)
- University of Al Maarif (IQ)
Publication Details
- Journal
- BMC Oral Health
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s12903-024-04801-w
- Citations
- 7
- Primary Topic
- Oral microbiology and periodontitis research
- Type
- article
- Field-Weighted Citation Impact
- 2.80